ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
The E3 Ligase RNF115 Aggravates Pathological Cardiac Hypertrophy via Ubiquitin-Mediated Degradation of SPTBN1.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Pathological cardiac hypertrophy represents an adaptive alteration in cardiac structure and function and serves as a critical process in heart failure. Ubiquitination, a classical post-translational modification that regulates protein function and degradation, plays a crucial role in cardiac hypertrophy. In this study, the E3 ubiquitin ligase ring finger protein 115 (RNF115) is identified as a key pro-hypertrophic factor. RNF115 expression is significantly elevated in heart tissues from patients with heart failure, in mice subjected to transverse aortic constriction (TAC) surgery, and in cardiomyocytes treated with angiotensin II (Ang II). RNF115 knockdown attenuates Ang II-induced cardiomyocyte hypertrophy in vitro, whereas cardiomyocyte-specific RNF115 knockout protects against TAC-induced cardiac hypertrophy and dysfunction in vivo. Mechanistically, upregulation of RNF115 promotes the ubiquitination and degradation of spectrin β, non-erythrocytic 1 (SPTBN1), causing filamentous actin (F-actin) depolymerization, thereby inactivates the Hippo-Yes associated protein (YAP) pathway and drives pro-hypertrophic gene expression. DTD (dithiocarbamate disulfide derivatives) is a potent inhibitor of RNF115 that suppresses SPTBN1 degradation and exerts a protective role in cardiac hypertrophy, indicating that inhibition of RNF115 may represent a potential therapeutic strategy for pathological cardiac hypertrophy and heart failure.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.